Article Information
PubMed
Print ISSN
Online ISSN
History
- Published online February 5, 2015.
Article Versions
- You are currently viewing an Earlier version of this article (February 5, 2015 - 07:23).
- View the most recent version of this article
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Hongbin Yu1,18,
- Suresh K. Balani2,
- Weichao Chen3,
- Donghui Cui4,
- Ling He5,
- William Griffith Humphreys6,
- Jialin Mao7,
- W. George Lai8,
- Anthony J. Lee9,
- Heng-Keang Lim10,
- Christopher MacLauchlin11,
- Chandra Prakash12,
- Sekhar Surapaneni13,
- Susanna Tse14,
- Alana Upthagrove15,
- Robert L. Walsky16,
- Bo Wen11, and
- Zhaopie Zeng17
- 1 Boehringer Ingelheim Pharmaceuticals. Inc.;
- 2 Takeda Pharmaceuticals International Co.;
- 3 Vertex Pharmaceuticals;
- 4 Merck Research Laboratories;
- 5 Daiichi Sankyo, Inc.;
- 6 Bristol-Myers-Squibb;
- 7 Genentech;
- 8 Eisai Pharmaceuticals;
- 9 Abbivie;
- 10 Janssen Research and Development;
- 11 GlaxoSmithKline;
- 12 Biogen Idec;
- 13 Celgene Corporation;
- 14 Pfizer Inc.;
- 15 Novartis Pharmaceuticals Corporation;
- 16 EMD Serono Research Institute;
- 17 Sanofi
- ↵18 E-mail: hongbin.yu{at}boehringer-ingelheim.com
Statistics from Altmetric.com
Article usage
In this issue
Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the IQ DMLG Metabolite Group
